Close

Executive Committee & Governing Boards

The Biotechnology Innovation Organization (BIO) is governed by the Executive Committee.  This committee consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board by the Chair and approved by the Board. The committee is authorized to exercise all powers of the Full Board, except for certain powers reserved for the Full Board under BIO's Bylaws. The BIO Board of Directors is comprised of all members of the Section Governing Boards.

BIO also has four Section Governing Boards who bring their opinion to bear on major issues affecting their specific area of biotechnology.  The four Section Governing Boards are Emerging Companies, Food & Agriculture, Health and Industrial & Environmental. 

Below are the staff contacts for the executive committee and each governing board.
Executive Committee: Tom DiLenge
Emerging Companies Section Governing Board: Cartier Esham
Food & Agriculture Section Governing Board: Dana O’Brien
Health Section Governing Board: Dan Durham
Industrial & Environmental Section Governing Board: Brent Erickson
 

Executive Committee

Executive Committee

  • John Maraganore, PhD Chair
    Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  • Ron Cohen, MD Immediate Past Chair
    President & CEO, Acorda Therapeutics, Inc
  • Bradford A. Zakes, MBA Treasurer
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Julie L. Gerberding, MD, MPH Secretary
    EVP, Strategic Communications, Global Public Policy, and Population Health, Merck
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals Incorporated
  • Albert Bourla, PhD
    Group President, Pfizer Innovative Health, Pfizer Inc.
  • Tjerk de Ruiter
    Chief Executive Officer, Corbion
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Paul J. Hastings
    Chairman and CEO, OncoMed Pharmaceuticals, Inc
  • Rachel K. King
    President & CEO, GlycoMimetics, Inc
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Philip W. Miller
    Global Regulatory & Government Affairs Lead, Monsanto Company
  • Michael Narachi
    President & Chief Executive Officer, Orexigen Therapeutics, Inc
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Alan Shaw, PhD
    President & CEO, Calysta
  • Christi L. Shaw
    U.S.Country President, Eli Lilly and Company
  • Jay P. Siegel, MD
    Chief Biotechnology Officer & Head of Scientific Strategy & Policy, Johnson & Johnson
  • Eddie J. Sullivan, PhD
    President & CEO, SAB Biotherapeutics
  • Section Governing Boards

    Emerging Companies Section Governing Board

  • Michael Narachi Chair
    President & Chief Executive Officer, Orexigen Therapeutics, Inc
  • Maxine Gowen, PhD Vice Chair
    President & CEO, Trevena, Inc.
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Katrine Bosley
    Chief Executive Officer, Editas Medicine
  • Jeffrey L. Cleland, PhD
    President & CEO, Graybug Vision, Inc.
  • Ron Cohen, MD
    President & CEO, Acorda Therapeutics, Inc
  • John F. Crowley, JD, MBA
    President & CEO, Amicus Therapeutics, Inc
  • Michelle Dipp, MD, PhD
    Chief Executive Officer, OvaScience, Inc.
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Deborah Dunsire, MD
    President & CEO, XTuit Pharmaceuticals, Inc
  • Peter S. Greenleaf
    Chairman & CEO, Sucampo Pharmaceuticals, Inc
  • Paul J. Hastings
    Chairman and CEO, OncoMed Pharmaceuticals, Inc
  • James Healy, MD, PhD
    General Partner, Sofinnova Ventures
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Emil D. Kakkis, MD, PhD
    Chief Executive Officer & President, Ultragenyx Pharmaceutical, Inc
  • Perry Karsen
    Chairman of the Board, Jounce Therapeutics, Inc.
  • Rachel K. King
    President & CEO, GlycoMimetics, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Jonathan Leff
    Chairman, Deerfield Institute, and Partner Deerfield Management, Deerfield Management Company LP
  • Nick Leschly
    President & CEO, bluebird bio
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Sandy Macrae
    President and CEO, Sangamo BioSciences, Inc
  • David Main
    CEO, Aquinox Pharmaceuticals, Inc.
  • John Maraganore, PhD
    Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  • Joel S. Marcus
    Chief Executive Officer, Alexandria Real Estate Equities, Inc
  • Jeffrey D. Marrazzo
    Co-Founder & CEO, Spark Therapeutics
  • John Mendlein, PhD
    CEO, aTyr Pharma, Inc.
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • Kenneth I. Moch
    President & CEO, Cognition Therapeutics
  • William J. Newell
    Chief Executive Officer, Sutro Biopharma, Inc
  • Christian W. Nolet
    Partner & Area Leader, Life Sciences, Ernst & Young, LLP
  • John A. Orwin
    President & CEO, Relypsa, Inc
  • Steven Paul
    President & CEO, Voyager Therapeutics, Inc.
  • Carlos V. Paya, MD, PhD
    Chief Executive Officer, Immune Design Corporation
  • Adelene Q. Perkins
    President & CEO, Infinity Pharmaceuticals, Inc.
  • Mark Pruzanski, MD
    Founder, President & CEO, Intercept Pharmaceuticals, Inc
  • Michael G. Raab
    Chief Executive Officer, Ardelyx Inc.
  • James Sapirstein, MBA, RPh
    Chief Executive Officer, Contravir Pharmaceuticals
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • David M. Stack
    President & CEO, Pacira Pharmaceuticals, Inc.
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Harold E. Van Wart, PhD
    President, CEO & Director, CymaBay Therapeutics
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • Christoph Westphal, PhD, MD
    Chair, CEO & President, Flex Pharma
  • Thomas G. Wiggans, MBA
    Founder & CEO, Dermira, Inc.
  • Robert J. Wills, PhD
    VP, Alliance Management - Business Development, Pharma Group, GTx, Inc
  • Bradford A. Zakes, MBA
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Food & Agriculture Section Governing Board

  • Eddie J. Sullivan, PhD Food & Ag Section Chair
    President & CEO, SAB Biotherapeutics
  • Philip W. Miller Food & Ag Section Vice Chair
    Global Regulatory & Government Affairs Lead, Monsanto Company
  • Paul Backman
    Head of Industry Relations, Syngenta
  • Brian Barker
    General Manager - US Seeds, Dow AgroSciences, LLC
  • Jerry Flint, PhD
    Vice President of the Industry Affairs & Regulatory Group, Dupont Corporation
  • Scott Holmstrom, PhD
    Senior Director, Late Stage External Innovation, Elanco
  • Dan Meagher, PhD
    President & CEO, Agrivida, Inc
  • Daphne Preuss, PhD
    President & CEO, Chromatin, Inc
  • Ronald L. Stotish, PhD
    Chief Executive Officer, Aqua Bounty Technologies, Inc
  • John R. Swart, PhD
    President, Exemplar Genetics, LLC
  • Frank Terhorst
    Global Head of Seeds, Bayer CropScience, Inc.
  • Health Section Governing Board

  • Ron Cohen, MD Chair
    President & CEO, Acorda Therapeutics, Inc
  • Paul J. Hastings Vice Chair
    Chairman and CEO, OncoMed Pharmaceuticals, Inc
  • Rachel K. King Immediate Past Chair
    President & CEO, GlycoMimetics, Inc
  • Michael Narachi Secretary
    President & Chief Executive Officer, Orexigen Therapeutics, Inc
  • Bill Anderson
    CEO & Head of North American Commercial Operations, Genentech, A Member of the Roche Group
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals Incorporated
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Jean-Jacques Bienaime
    President & CEO, BioMarin Pharmaceutical, Inc
  • Chris Boerner
    President and Head of US Commercial Business, Bristol-Myers Squibb Company
  • Katrine Bosley
    Chief Executive Officer, Editas Medicine
  • Albert Bourla, PhD
    Group President, Pfizer Innovative Health, Pfizer Inc.
  • Carsten Brunn
    Head of Pharmaceuticals, Americas Region, Bayer Corporation
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Mark Enyedy
    President & CEO, ImmunoGen, Inc
  • William Fitzsimmons, MS, PharmD
    Divisional EVP for Global Regulatory Affairs & Global Clinical &Research Quality, Astellas Pharma Inc.
  • Julie L. Gerberding, MD, MPH
    EVP, Strategic Communications, Global Public Policy, and Population Health, Merck
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Peter S. Greenleaf
    Chairman & CEO, Sucampo Pharmaceuticals, Inc
  • Christopher P. Healey
    Vice President, Public Affairs, Grifols
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Bill Hinshaw
    Executive Vice President and Head, Novartis
  • Herve Hoppenot
    President & CEO, Incyte Corporation
  • Emil D. Kakkis, MD, PhD
    Chief Executive Officer & President, Ultragenyx Pharmaceutical, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Joseph LaRosa
    Senior Vice President, General Counsel and Secretary, Regeneron Pharmaceuticals, Inc
  • John Lepore, MD
    SVP, MPC TA, GlaxoSmithKline plc
  • Nick Leschly
    President & CEO, bluebird bio
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Elizabeth Lewis
    Chief Counsel, Global Oncology Business Unit, Patient Advocacy, Takeda Oncology
  • Sabine Luik, MD, MPH
    Senior Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim
  • John Maraganore, PhD
    Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  • Kiran Mazumdar-Shaw
    Chairperson & Managing Director, Biocon Limited
  • Paul McKenzie, PhD
    EVP, Pharmaceutical Operations & Technology, Biogen
  • Clive A. Meanwell, MD, PhD
    Founder, Chairman & CEO, The Medicines Company
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • Jim Meyers
    Executive Vice President, Worldwide Commercial Operations, Gilead Sciences, Inc
  • Michael M. Morrissey, PhD
    President & CEO, Exelixis, Inc
  • C. David Nicholson, PhD
    Chief R&D Officer, Allergan PLC
  • Joshua J. Ofman, MD
    SVP, Global Value, Access & Policy, Amgen Inc.
  • Adelene Q. Perkins
    President & CEO, Infinity Pharmaceuticals, Inc.
  • Anne Phillips, MD
    SVP, Clinical, Medical & Regulatory Affairs, Novo Nordisk
  • Gary Phillips, MD
    Senior Vice President & Chief Strategy Officer , Mallinckrodt Pharmaceuticals
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Robert Repella
    Executive Vice President, Global Commercial Operations, CSL Behring
  • Howard W. Robin
    Inc, Nektar Therapeutics, Inc
  • James Sapirstein, MBA, RPh
    Chief Executive Officer, Contravir Pharmaceuticals
  • Christi L. Shaw
    U.S.Country President, Eli Lilly and Company
  • Jay P. Siegel, MD
    Chief Biotechnology Officer & Head of Scientific Strategy & Policy, Johnson & Johnson
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • Mark Skaletsky
    Chairman & CEO, Fenway Pharmaceuticals, Inc
  • Scott Smith
    President and COO, Celgene Corporation
  • David M. Stack
    President & CEO, Pacira Pharmaceuticals, Inc.
  • Perry Sternberg
    Head, US Commercial, Shire
  • James Sullivan, PhD
    Vice President, Pharmaceutical Discovery, AbbVie Inc.
  • Jean-Christophe Tellier
    Chief Executive Officer & Chairman, UCB SA
  • Helen Torley, MRCP
    President & CEO, Halozyme Therapeutics, Inc
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • Neil K. Warma
    President & CEO, Opexa Therapeutics
  • H. Thomas Watkins Immediate Past Chair
    Chair Emeritus, BIO, Biotechnology Innovation Organization
  • Allen Waxman
    Executive Vice President, Market Access, Government Affairs & Corporate Advocacy, Eisai, Inc
  • Rick E. Winningham
    Chief Executive Officer, Theravance Biopharma US, Inc.
  • Gary Zieziula
    President & Managing Director, North America, EMD Serono, Inc
  • Industrial & Environmental Section Governing Board

  • Alan Shaw, PhD I&E Section Chair
    President & CEO, Calysta
  • Tjerk de Ruiter I&E Section Vice Chair
    Chief Executive Officer, Corbion
  • Doug Berven
    Vice President, Corporate Affairs, Poet, LLC
  • Jennifer Holmgren, MBA, PhD
    Chief Executive Officer, LanzaTech
  • Mark Jones, PhD
    Executive Strategy and Communications Director, The Dow Chemical Company
  • Benjamin R. Knudsen
    Head of Biotechnology NA/GM, BASF Enzymes LLC
  • John G. Melo
    Chief Executive Officer, Amyris, Inc.
  • Adam Monroe
    President, Americas, Novozymes
  • Anna Rath
    President & CEO, NexSteppe
  • Vincent Sewalt
    Senior Director, Product Stewardship & Regulatory, Dupont Corporation
  • Christopher Standlee
    Vice President, ICM, Inc
  • Hugh C. Welsh, JD
    President, DSM North America
  • Roger Wyse, PhD
    Managing Director, Spruce Capital Partners